

Human stem cells from patients with genetically derived cardiomyopathy

Background

Bayer's Pharmaceuticals Research & Development division is working on potential future therapies for patients with Cardiomyopathies of a genetic background for whom a therapy is currently not available.

We would like to use the stem cells to generate heart muscle cells and to investigate the differences of those cells in comparison to a healthy state to develop new therapeutic opportunities.

What we're looking for

We are seeking for stem cells from patients with dilated cardiomyopathies (e.g. laminopathy or others). The genetic defect in those patients causing the disease should be known. Further, we would need certain clinical parameters of those patients. We would NOT use the cells itself for clinical research & development.

Solutions of interest include:

- iPSCs from patients with dilated cardiomyopathies

Our must-have requirements are:

- The genetic defect in those patients causing the disease must be known
- The allowance by the donors to do research & development with the results of investigating those cells to develop human therapies.
- The allowance to use the iPSCs to expand, reproduce, do gene sequencing, do expression analysis and further utilize
- You must be able to show us the detailed wording of the patient informed consent, if requested.

Our nice-to-have requirements are:

- Proven differentiation into cardiomyocytes
- Examined phenotype of cells
- Heart tissue from those patients instead of cells

What's out of scope:

- Embryonic stems cells
- Cells derived from animals

Acceptable technology readiness levels (TRL): Levels 2-4

1. Basic principles observed
2. Concept development
3. Experimental proof of concept
4. Validated in lab conditions
5. Validated in relevant environment
6. Demonstrated in relevant environment
7. Regulatory approval
8. Product in production
9. Product in market

What we can offer you

Eligible partnership models:

- **Sponsored research**
- **Licensing**
- **Supply/purchase**

Benefits:

Sponsored Research

We might consider sponsored research at some time: Potential future research collaboration in such field on a broader level, potential involvement of institution's personnel on consultancy basis

Who we are

Bayer is a German multinational pharmaceutical and life sciences company with a more than 150-year history and core competencies in the areas of health care and agriculture.

Reviewers

Fiona Mack

VP Head Co.Lab Cambridge

Christopher Paschall

Academic Liaison

Please contact the University of South Florida Technology Transfer office representative for submission – Karla Schramm at kschramm@usf.edu